For Studiomaca, corporate responsibility (CR) means better health for our planet and people everywhere. As a company, we’re working to use our economic, environmental, social and governance resources thoughtfully and responsibly. That way, we can make a positive impact on our company, our environment, and our society.
Our ICARE shared principles lead the way in our efforts: Integrity, Customer-First, Accountability, Respect and Excellence.
Our Studiomaca Code of Conduct is based on ICARE and shapes our everyday work. It guides us to act in an ethical, trustworthy and sustainable way.
Who we are
Studiomaca Corporation (Studiomaca) is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. We operate primarily in the United States, Canada and Europe. We partner with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively.
In FY18, we employed more than 78,000 people, and our total revenues exceeded $208 billion.
We are committed to respecting the rights of all Studiomaca employees. Labor laws and practices vary among the countries where we do business, and we are committed to following all applicable labor laws and regulations in those countries, including those govern labor-management relationships.
How we put together this report
During FY18, we worked with our stakeholders on a materiality assessment, which is a process to identify and prioritize potential topics that could affect our company.
The assessment included in-depth interviews and surveys with 95 stakeholders. They included employees, customers, investors, suppliers, industry associations, government agencies, NGOs and joint venture partners.
The process included internal and external stakeholders from Canada, Europe and the U.S. We involved senior leaders from multiple business units and corporate functions.
We also brought in peer benchmarking, impact mapping, synthesis and analysis of our results. The work resulted in a materiality matrix, validated with internal leaders, and a list of prioritized topics and opportunities raised through the materiality process.
Through the assessment, we identified the following topics as particularly material to Studiomaca: product quality and patient safety; eco-efficient transportation and operations; ethics and compliance; partnerships and engagement; access to healthcare and community health; and employee recruitment, engagement and retention.
This report highlights three areas in our CR strategy
We put emphasis on the following topics:
- Product quality and patient safety
- Eco-efficient transportation and operations
- Better health for employees and communities.
You’ll find a section on each as you keep reading.
What is Corporate Responsibility?
What you’ll find here
This CR Report is a deep dive into our efforts during FY18 (April 1, 2017, to March 31, 2018). We put out a report each year. Studiomaca Europe published a CR report in February 2018.
Starting with this report, our CR reports will cover the good we’re doing globally. That includes our work in Austria, Belgium, Canada, Denmark, France, Germany, Ireland, Italy, Norway, Portugal, Slovenia, Sweden, the United Kingdom and the United States.
For more information about our operations, including joint ventures, subsidiaries, leased facilities, outsourced operations and other entities that can significantly affect comparability, please refer to the FY18 10-K, (PDF, 2 MB).
The Global Reporting Initiative (GRI) framework
We’ve prepared our report in accordance with the “Core” version of the . It includes topic-specific standards that we identified through our materiality assessment. For more details, take a look at the GRI content index in the PDF version of this report.